TargImmune Therapeutics: Funding, Investors & Team (Sep 2026)
TargImmune Therapeutics AG is a private Swiss-based biotechnology company focused on drug development using novel targeted onco-immunotherapies. The Company’s principal technology is the CTPIC technology platform that utilizes a non-viral vector to target and destroy cancer cells that over-express certain receptors while simultaneously eliciting an immune response against the cancer cells.
TargImmune Therapeutics has raised $19.3M across 1 funding round on record, the most recent an undisclosed round of $19.3M announced in Jul 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
TargImmune Therapeutics Company Profile and Key Stats
Latest funding round on record: Jul 2021.
TargImmune Therapeutics Funding Rounds
TargImmune Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
TargImmune Therapeutics Funding Compared to Other Biotechnology Startups
TargImmune Therapeutics' latest round of $19.3M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like TargImmune Therapeutics in Biotechnology and Basel
Companies Similar to TargImmune Therapeutics
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
TargImmune Therapeutics Funding FAQs
What does TargImmune Therapeutics do?
TargImmune Therapeutics AG is a private Swiss-based biotechnology company focused on drug development using novel targeted onco-immunotherapies. The Company’s principal technology is the CTPIC technology platform that utilizes a non-viral vector to target and destroy cancer cells that over-express certain receptors while simultaneously eliciting an immune response against the cancer cells.
How much funding has TargImmune Therapeutics raised?
TargImmune Therapeutics has raised $19.3M across 1 round on record. The most recent is an undisclosed round of $19.3M announced in Jul 2021.
When did TargImmune Therapeutics last raise funding?
TargImmune Therapeutics' most recent funding round on record is an undisclosed round of $19.3M, announced in Jul 2021.
Who is the CEO of TargImmune Therapeutics?
Paolo Fundaro is listed as CEO at TargImmune Therapeutics.
Where is TargImmune Therapeutics headquartered?
TargImmune Therapeutics is based in Basel, Basel-Stadt, Switzerland.
How many employees does TargImmune Therapeutics have?
TargImmune Therapeutics is in the 11-50 employee band.
How does TargImmune Therapeutics' funding compare to other Biotechnology startups?
TargImmune Therapeutics' latest round of $19.3M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's TargImmune Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for TargImmune Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.